3177 results for «391»
3177 results
Ultrasound renal denervation is now guideline-recommended: how do I get started?
20 May 2025 – From EuroPCR 2025
Ultrasound renal denervation (uRDN) is now guideline-recommended—are you ready to bring it into practice? This EuroPCR 2025 session offers everything you need to get started: review key results from Sham-controlled and off-medication trials confirming the efficacy and safety of RDN; understand why both the ESC and...
Valve choice - Shaping index procedures and lifetime patient management
22 May 2025 – From EuroPCR 2025
This session addresses recent advancements and ongoing challenges in transcatheter aortic valve implantation (TAVI), with a particular focus on valve selection during index procedures. Presentations include data from the Accurate IDE trial, highlighting the prognostic implications of valve underexpansion. A clinical case involving an 80-year-old patient with severe...
Complex PCI in calcific coronary artery disease - LIVE Case
20 May 2025 – From EuroPCR 2025
A 76-year-old male patient presented with a significant history of coronary artery disease: CABG with LIMA/LAD and RIMA/OM (1996), RCA PCI with BVS (2016), OM PCI (2017), RIMA occlusion and OM retenosis treated with DCB (2022) with preserved LV. He was admitted for pre-operative evaluation prior...
Why should laser atherectomy be part of your complex PCI algorithm?
21 May 2025 – From EuroPCR 2025
Watch this EuroPCR 2025 session to see how ELCA can make the difference in two challenging cases: a severely calcified, undilatable lesion, and an uncrossable one. Learn how pre- and peri-procedural imaging (CT, IVUS, OCT) supports tailored decision-making, and how ELCA enables safe and effective lesion...
How to manage coronary artery disease in TAVI candidates?
20 May 2025 – From EuroPCR 2025
Understand the comprehensive management of coronary artery disease (CAD) in patients undergoing transcatheter aortic valve implantation (TAVI). This session reviews evidence-based evaluation, decision-making, and treatment strategies for significant coronary lesions, including severe left main and multivessel disease, illustrated through detailed case studies.
How a new generation of coronary sinus reducer can significantly expand treatment options for patients with coronary microvascular dysfunction
21 May 2025 – From EuroPCR 2025
Discover the latest on managing coronary microvascular dysfunction (CMD) with insights from EuroPCR 2025. This session explores how physiology testing helps identify CMD endotypes in the cathlab and highlights the limitations of ETT for patients experiencing angina or dyspnea at rest. Learn about the A-FLUX coronary...
Role of imaging in ACS: from non-invasive to invasive investigations
20 May 2025 – From EuroPCR 2025
Explore the critical role of imaging in acute coronary syndrome (ACS) from non-invasive coronary CT angiography to invasive intracoronary imaging modalities. This session covers detection of culprit lesions, diagnostic strategies, and PCI optimization through real-world case examples.
Mitral hotline: new devices
20 May 2025 – From EuroPCR 2025
Stay updated on emerging devices in mitral valve repair and replacement with this session covering novel technologies including transcatheter edge-to-edge repair (TEER), posterior leaflet restoration, transfemoral mitral annuloplasty, and a first-in-human transseptal TMVR system. Clinical trial data and early feasibility experiences provide valuable insights into advancing...
Mitral and tricuspid hotline: long-term outcomes
20 May 2025 – From EuroPCR 2025
Review long-term outcomes of transcatheter edge-to-edge repair (TEER) for mitral and tricuspid valve disease in this session. Highlights include pivotal trial results, mortality risk prediction tools, management of procedural failures, and real-world data, providing comprehensive insights into patient prognosis and therapeutic impact.
Imaging skills for successful TAVI procedure
21 May 2025 – From EuroPCR 2025
Enhance your imaging skills essential for successful TAVI procedures. This session covers complex scenarios such as left circumflex coronary artery anomalies, valve infolding risks with new platforms, bioprosthesis dysfunctions, procedural adaptations when faced with challenges, and zero-contrast TAVI techniques.
Advancing the standard of care in PCI with Bioadaptor: from simple to complex
21 May 2025 – From EuroPCR 2025
This session provides an in-depth overview of Bioadapter technology and its potential to overcome the limitations of current drug-eluting stents (DES) in percutaneous coronary intervention (PCI). Speakers present data from recent trials, including the Bioadapter RCT and the Infinity Sweetheart study, demonstrating a reduction in target lesion...
3-year Efficacy Outcomes From the Spyral Htn-on Med Pilot Study: Long Term Effect of Renal Denervation On Blood Pressure Reduction in Patients on Antihypertension Medications
22 Mar 2022
Ali Nazmi Calik provides his take on the long-term results of the SPYRAL HTN-ON MED trial which demonstrated the durable efficacy and safety of RDN in patients who are already on one to three antihypertensive drugs.
Author
GLORIOUS - Efficacy of restrictive versus liberal oxygenation or Exenatide in patients undergoing coronary artery bypass grafting or aortic valve replacement – a randomised clinical trial
21 Nov 2024
Edoardo Zancanaro provides his take on the GLORIOUS trial presented by Sebastian Wiberg at AHA 2024 in Chicago.
Author
EuroPCR 2025 – The FAITAVI trial: angiography versus physiology-guided PCI in patients undergoing TAVI – 12-month follow-up data
21 May 2025
Paris, France, 20-23 May 2025. The EuroPCR Course Directors have selected 3 major late-breaking trials that will be presented for the first time during the 2025 edition of EuroPCR. These trials were selected because of their design, results, and potential to impact practice, among them is the...
The 2023 ESH Hypertension Guidelines revisit the role of renal denervation
05 Sep 2023
The 2023 European Society of Hypertension (ESH) guidelines were recently presented at the 32nd annual European Meeting on Hypertension and Cardiovascular Protection and simultaneously published in the Journal of Hypertension.1 While wide parts of the guidelines do not substantially differ from the previous 2018 European Society...
Author
Author
The AQUATIC trial: Assessment of quitting versus using aspirin therapy in patients with stabilized coronary artery disease after stenting who require long-term oral anticoagulation
01 Sep 2025
Chiara De Biase provides her take on the results of AQUATIC presented by Martine Gilard at ESC Congress 2025 in Madrid.
Author
![The AQUATIC trial [Assessment of quitting versus using aspirin therapy in patients with stabilized coronary artery disease after stenting who require long-term oral anticoagulation: Rationale for and design of the AQUATIC double-blind randomized trial]](https://www.pcronline.com/var/pcrov3/storage/images/pcronline/news/congress-coverages/esc/2025/aquatic-trial-quitting-versus-using-aspirin-therapy-patients-stabilized-cad-stenting-long-term-oral-anticoagulation/27448089-9-eng-GB/The-AQUATIC-trial-Assessment-of-quitting-versus-using-aspirin-therapy-in-patients-with-stabilized-coronary-artery-disease-after-stenting-who-requi_image_responsive_6.jpg)
NEO-MINDSET: Early withdrawal of aspirin after percutaneous coronary intervention for acute coronary syndrome
02 Sep 2025
Daniele Giacoppo reports and provides his perspective on the main results of the ambitious NEOMINDSET trial, presented by Pedro Lemos from the Hospital Israelita Albert Einstein, São Paulo, Brazil, during a Late Breaking Trials session at the ESC Congress 2025 in Madrid, and simultaneously published in the New...
Author
